查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574832

美國全身麻醉劑市場規模、佔有率、趨勢分析報告：按藥物、途徑途徑、最終用途、應用、國家/地區、細分市場預測，2024-2030 年

U.S. General Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug, By Route of Administration, By End-use, By Application, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 70 Pages | 商品交期: 2-10個工作天內

價格

美國全身麻醉劑市場成長與趨勢：

根據 Grand View Research, Inc. 預測，到 2030 年，美國全身麻醉劑市場規模預計將達到 20.3 億美元，2024 年至 2030 年複合年成長率為 2.8%。

這一成長主要是由手術數量的增加所推動的。美國麻醉醫師協會 (ASA) 強調，由於人口老化、慢性病盛行率增加以及手術技術的進步，手術數量持續增加。美國疾病管制與預防中心 (CDC) 2024 年 2 月報告稱，大約 1.29 億美國人患有至少一種主要慢性疾病，例如癌症、心臟病、糖尿病或高血壓。慢性病的高盛行率導致大量心血管和其他外科手術，從而導致對有效全身麻醉劑的需求增加。

麻醉技術的進步也是重要的促進因素。REMIFENTANIL等超短效麻醉劑創新可以更好地控制麻醉深度並縮短恢復時間，從而改善患者的治療效果並推動市場成長。此外，先進的輸送系統和監測技術（包括自動麻醉輸送系統）的發展透過提高準確性和安全性正在徹底改變麻醉實踐。

監管的發展也扮演著重要角色。 FDA 對突破性療法的快速核准途徑有助於快速獲得新的有效麻醉劑。例如，最近核准的新型緩釋性麻醉劑ZYNRELEF™ 展示了監管進步如何支持創新產品的採用。

美國全身麻醉劑市場報告亮點

  • 以藥物來看，Propofol細分預計將在 2023 年佔據市場主導地位，收益佔有率將達到 25.4%，並且預計在預測期內將以 3.4% 的複合年成長率成長最快。
  • 按途徑途徑分類，靜脈注射在 2023 年佔據最大收益佔有率，為 63.1%，預計在預測期內將以 3.0% 的最快複合年成長率成長。
  • 從應用來看，全膝關節關節重建和全髖置換術佔據了市場主導地位，並佔據了可觀的收益佔有率。
  • 按最終用途分類，醫院細分市場佔據主導地位，到 2023 年，收益佔有率將達到 67.2%。醫院是需要全身麻醉的大型手術和複雜醫療程序的主要場所。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國全身麻醉劑市場變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國全身麻醉劑市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國全身麻醉劑市場：藥物預估及趨勢分析

  • 美國全身麻醉劑市場：藥物儀表板
  • 美國全身麻醉劑市場：藥物波動分析
  • 美國全身麻醉劑市場：按藥物分類的收益
  • SEVOFLURANE
  • Propofol
  • Dexmedetomidine
  • REMIFENTANIL
  • DESFLURANE
  • 咪達唑侖
  • 其他

第5章美國全身麻醉劑市場：給藥途徑預估及趨勢分析

  • 美國全身麻醉劑市場：給藥途徑儀表板
  • 美國全身麻醉劑市場：給藥途徑變異分析
  • 按管理途徑的收益
  • 靜脈
  • 吸入型

第6章美國全身麻醉劑市場：最終用途估計與趨勢分析

  • 美國全身麻醉劑市場：最終用途儀表板
  • 美國全身麻醉劑市場：最終用途變化分析
  • 按最終用途分類的收益
  • 醫院
  • 門診手術中心
  • 其他

第7章美國全身麻醉劑市場：應用估算與趨勢分析

  • 美國全身麻醉劑市場：應用儀表板
  • 美國全身麻醉劑市場：應用變化分析
  • 按使用情況分類的收益
  • 心血管手術
    • 2018-2030 年心血管手術市場估計與預測
  • 癌症
    • 2018-2030 年癌症市場估計與預測
  • 一般外科
    • 2018-2030 年其他市場估計與預測
  • 膝關節/髖關節置換術
    • 2018-2030 年其他市場估計與預測
  • 其他
    • 2018-2030 年其他市場估計與預測

第8章美國全身麻醉劑市場：按藥物、給藥途徑的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：

第9章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 2023年主要企業市場佔有率分析
    • Baxter International Inc.
    • AstraZeneca
    • AbbVie Inc.
    • B. Braun Melsungen AG
    • Fresenius SE &Co. KgaA
    • Pfizer
    • Hospira Inc.
    • Aspen Pharmacare Holdings Limited
    • Hikama Pharmaceuticals plc
    • Abbott Laboratories
Product Code: GVR-4-68040-451-8

U.S. General Anesthesia Drugs Market Growth & Trends:

The U.S. general anesthesia drugs market size is projected to reach USD 2.03 billion by 2030, and is anticipated to grow at a CAGR of 2.8% from 2024 to 2030, according to Grand View Research, Inc. The rising number of surgical procedures primarily drives this growth. The American Society of Anesthesiologists (ASA) highlights a consistent increase in surgeries, attributed to an aging population, the growing prevalence of chronic diseases, and advancements in surgical techniques. The CDC reported in February 2024 that approximately 129 million Americans have at least one major chronic disease, such as cancer, heart disease, diabetes, and hypertension. This high prevalence of chronic conditions necessitates numerous cardiovascular and other surgeries, which in turn drives the demand for effective general anesthesia drugs.

Advancements in anesthesia technology are another critical driver. Innovations such as ultra-short-acting anesthetics, like remifentanil, offer improved control over anesthesia depth and faster recovery times, enhancing patient outcomes and driving market growth. Additionally, the development of advanced delivery systems and monitoring technologies, including automated anesthesia delivery systems, has revolutionized anesthesia practices by improving precision and safety.

Regulatory developments also play a significant role. The FDA's expedited approval pathways for breakthrough therapies facilitate quicker access to new and effective anesthetics. For instance, the recent approval of ZYNRELEFTM, a novel extended-release anesthetic, illustrates how regulatory advancements support the introduction of innovative products.

U.S. General Anesthesia Drugs Market Report Highlights:

  • Based on drug, the propofol segment dominated the market with a substantial revenue share of 25.4% in 2023 and is also expected to grow at the fastest CAGR of 3.4% during the forecast period, driven by its widespread use as a preferred agent for induction and maintenance of general anesthesia.
  • Based on route of administration, the intravenous segment held the largest revenue share of 63.1% in 2023 and is also expected to grow at the fastest CAGR of 3.0% during the forecast period
  • Based on application, the knee and hip replacements segment dominated the market, capturing a substantial revenue share.
  • Based on end use, the hospitals segment dominated the market, capturing a substantial revenue share of 67.2% in 2023. Hospitals are the primary settings for major surgeries and complex medical procedures that require general anesthesia.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Route of Administration
    • 1.2.3. End Use
    • 1.2.4. Application
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Outlook
    • 2.2.2. Route of Administration
    • 2.2.3. End Use
    • 2.2.4. Application
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. General Anesthesia Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing Volume Of Surgical Procedures
      • 3.2.1.2. Advancements In Anesthesia Technology
      • 3.2.1.3. Regulatory Developments
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Regulatory and Compliance Challenges
      • 3.2.2.2. Adverse Effects and Safety Concerns
  • 3.3. U.S. General Anesthesia Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis

  • 4.1. U.S. General Anesthesia Drugs Market: Drug Dashboard
  • 4.2. U.S. General Anesthesia Drugs Market: Drug Movement Analysis
  • 4.3. U.S. General Anesthesia Drugs Market by Drug, Revenue
  • 4.4. Sevoflurane
    • 4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Propofol
    • 4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Dexmedetomidine
    • 4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Remifentanil
    • 4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Desflurane
    • 4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Midazolam
    • 4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. U.S. General Anesthesia Drugs Market: Route of Administration Dashboard
  • 5.2. U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
  • 5.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Intravenous
    • 5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Inhaled
    • 5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis

  • 6.1. U.S. General Anesthesia Drugs Market: End Use Dashboard
  • 6.2. U.S. General Anesthesia Drugs Market: End Use Movement Analysis
  • 6.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Ambulatory Surgical Centers
    • 6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. General Anesthesia Drugs Market: Application Estimates & Trend Analysis

  • 7.1. U.S. General Anesthesia Drugs Market: Application Dashboard
  • 7.2. U.S. General Anesthesia Drugs Market: Application Movement Analysis
  • 7.3. U.S. General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
  • 7.4. Heart Surgeries
    • 7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Cancer
    • 7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. General Surgery
    • 7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Knee and hip replacements
    • 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Other
    • 7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
    • 8.2.1. U.S.
      • 8.2.1.1. Key country dynamics
      • 8.2.1.2. Regulatory framework/ reimbursement structure
      • 8.2.1.3. Competitive scenario
      • 8.2.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Vendor Landscape
    • 9.2.1. List of key distributors and channel partners
    • 9.2.2. Key company market share analysis, 2023
    • 9.2.3. Baxter International Inc.
      • 9.2.3.1. Company overview
      • 9.2.3.2. Financial performance
      • 9.2.3.3. Drug benchmarking
      • 9.2.3.4. Strategic initiatives
    • 9.2.4. AstraZeneca
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Drug benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. AbbVie Inc.
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Drug benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. B. Braun Melsungen AG
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Drug benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. Fresenius SE & Co. KgaA
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Drug benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Pfizer
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Drug benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. Hospira Inc.
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Drug benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. Aspen Pharmacare Holdings Limited
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Drug benchmarking
      • 9.2.10.4. Strategic initiatives
    • 9.2.11. Hikama Pharmaceuticals plc
      • 9.2.11.1. Company overview
      • 9.2.11.2. Financial performance
      • 9.2.11.3. Drug benchmarking
      • 9.2.11.4. Strategic initiatives
    • 9.2.12. Abbott Laboratories
      • 9.2.12.1. Company overview
      • 9.2.12.2. Financial performance
      • 9.2.12.3. Drug benchmarking
      • 9.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List Of Abbreviation
  • Table 2 U.S. General Anesthesia Drugs Market, By Drug, 2018 - 2030 (USD Million)
  • Table 3 U.S. General Anesthesia Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 4 U.S. General Anesthesia Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 5 U.S. General Anesthesia Drugs Market, Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. General Anesthesia Drugs Market: Market Outlook
  • Fig. 10 Colorectal Surgery Competitive Insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 U.S. General Anesthesia Drugs Market Driver Impact
  • Fig. 14 U.S. General Anesthesia Drugs Market Restraint Impact
  • Fig. 15 U.S. General Anesthesia Drugs Market Strategic Initiatives Analysis
  • Fig. 16 U.S. General Anesthesia Drugs Market: Drug Movement Analysis
  • Fig. 17 U.S. General Anesthesia Drugs Market: Drug Outlook And Key Takeaways
  • Fig. 18 Sevoflurane market estimates and forecast, 2018 - 2030
  • Fig. 19 Propofol market estimates and forecast, 2018 - 2030
  • Fig. 20 Dexmedetomidine market estimates and forecast, 2018 - 2030
  • Fig. 21 Remifentanil market estimates and forecast, 2018 - 2030
  • Fig. 22 Desflurane market estimates and forecast, 2018 - 2030
  • Fig. 23 Midazolam market estimates and forecast, 2018 - 2030
  • Fig. 24 Others market estimates and forecast, 2018 - 2030
  • Fig. 25 U.S. General Anesthesia Drugs Market: Route of Administration Movement Analysis
  • Fig. 26 U.S. General Anesthesia Drugs Market: Route of Administration Outlook And Key Takeaways
  • Fig. 27 Intravenous market estimates and forecast, 2018 - 2030
  • Fig. 28 Inhaled market estimates and forecast, 2018 - 2030
  • Fig. 29 U.S. General Anesthesia Drugs Market: End Use Movement Analysis
  • Fig. 30 U.S. General Anesthesia Drugs Market: End Use Outlook And Key Takeaways
  • Fig. 31 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 32 Ambulatory Surgical Centers market estimates and forecast, 2018 - 2030
  • Fig. 33 Others market estimates and forecast, 2018 - 2030
  • Fig. 34 U.S. General Anesthesia Drugs Market: Application Movement Analysis
  • Fig. 35 U.S. General Anesthesia Drugs Market: Application Outlook And Key Takeaways
  • Fig. 36 Heart Surgeries market estimates and forecast, 2018 - 2030
  • Fig. 37 Cancer market estimates and forecast, 2018 - 2030
  • Fig. 38 General Surgery market estimates and forecast, 2018 - 2030
  • Fig. 39 Knee and hip replacements market estimates and forecast, 2018 - 2030
  • Fig. 40 Other market estimates and forecast, 2018 - 2030
  • Fig. 41 Market share of key market players- U.S. General Anesthesia Drugs Market